|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Maastricht University Medical Center ZonMw: The Netherlands Organisation for Health Research and Development |
| Information provided by: | Maastricht University Medical Center |
| ClinicalTrials.gov Identifier: | NCT00512967 |
Purpose
Reactive oxygen species (ROS) are suggested to play a pivotal role in ILD. Little is known, however, about the endogenous antioxidant levels in ILD that can offer protection against ROS. It is expected that the high amount of ROS present in ILD will reduce the antioxidant levels. Therefore, antioxidant therapy to strengthen this reduced antioxidant defense might be efficacious in ILD treatment. Since ROS are capable of initiating and mediating inflammation, antioxidant therapy might also mitigate elevated inflammation. A candidate for antioxidant therapy is the flavonoid quercetin that is known for its anti-oxidative and anti-inflammatory capacities.
The aim of the present study is to determine the antioxidant and inflammatory status in ILD, i.e. sarcoidosis and idiopathic pulmonary fibrosis (IPF). Furthermore, to evaluate the possible anti-inflammatory effects of antioxidants, the effect of quercetin will be examined on the ex vivo LPS-induced cytokine production in ILD
| Condition |
|
Interstitial Lung Diseases Sarcoidosis Idiopathic Pulmonary Fibrosis COPD |
| MedlinePlus related topics: | Antioxidants Pulmonary Fibrosis Sarcoidosis Stress |
| ChemIDplus related topics: | Quercetin |
| Study Type: | Observational |
| Study Design: | Case-Only, Cross-Sectional |
| Official Title: | The Inflammatory and Antioxidant Status in Pulmonary Sarcoidosis, Idiopathic Pulmonary Fibrosis and COPD: a Potential Role for Antioxidants |
blood samples were collected
| Enrollment: | 76 |
| Study Start Date: | September 2005 |
| Study Completion Date: | June 2006 |
| Groups/Cohorts |
|
sarcoidosis
21 onset patients, non-treated
|
|
IPF
15 IPF patients, partially treated
|
|
COPD
15 COPD patients within 24 hours after their last exacerbation
|
|
controls
25 healthy controls, matched for age and gender
|
![]() |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
lung patients visiting the out-patient clinic of the Academic Hospital Maastricht
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Netherlands | |||||
| Maastricht University | |||||
| Maastricht, Netherlands, 6224 LH | |||||
| Maastricht University Medical Center |
| ZonMw: The Netherlands Organisation for Health Research and Development |
| Study Chair: | Aalt Bast, PhD | Maastricht University Medical Center |
| Principal Investigator: | Agnes W Boots, PhD | Maastricht University Medical Center |
| Study Director: | Guido R Haenen, PhD | Maastricht University Medical Center |
More Information
| Responsible Party: | Maastricht University ( Dr. A.W. Boots ) |
| Study ID Numbers: | MEC 03-112 |
| First Received: | July 19, 2007 |
| Last Updated: | February 25, 2008 |
| ClinicalTrials.gov Identifier: | NCT00512967 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
|
|
|
|